Chardan Capital Comments on Krystal Biotech FY2025 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities researchers at Chardan Capital lowered their FY2025 EPS estimates for Krystal Biotech in a research note issued on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of $5.50 per share for the year, down from their prior estimate of $6.15. Chardan Capital currently has a “Buy” rating and a $219.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). The business had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%.

A number of other equities research analysts have also commented on the stock. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Guggenheim reduced their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Finally, Citigroup upped their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $218.63.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $139.43 on Monday. The firm’s fifty day moving average is $170.75 and its 200-day moving average is $169.76. Krystal Biotech has a 52 week low of $131.71 and a 52 week high of $219.34. The firm has a market cap of $4.03 billion, a P/E ratio of 46.63 and a beta of 0.79.

Insider Activity at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. The trade was a 1.68% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

Institutional Trading of Krystal Biotech

Institutional investors have recently made changes to their positions in the company. Public Sector Pension Investment Board grew its position in Krystal Biotech by 27.4% during the first quarter. Public Sector Pension Investment Board now owns 80,264 shares of the company’s stock valued at $14,472,000 after buying an additional 17,254 shares during the period. Nuveen LLC bought a new position in Krystal Biotech during the first quarter valued at about $42,223,000. Covestor Ltd grew its position in Krystal Biotech by 111.4% during the first quarter. Covestor Ltd now owns 1,497 shares of the company’s stock valued at $270,000 after buying an additional 789 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Krystal Biotech during the first quarter valued at about $466,000. Finally, Cynosure Group LLC grew its position in Krystal Biotech by 7.5% during the first quarter. Cynosure Group LLC now owns 3,902 shares of the company’s stock valued at $704,000 after buying an additional 272 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).